Organon & Co updates earnings timing, shares watched by health care investors

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 22:40.

Organon & Co Inc. (US68622V1061) is preparing for its next round of financial and strategic updates, with investors looking at the timetable for the New Jersey based women’s health group listed on the NYSE. The company’s investor relations calendar points to the next quarterly results and related webcasts as the key dates for Organon shares, according to the latest updates on its website. Organon investor relations calendar

Upcoming earnings and NYSE context

Organon & Co Inc. was spun off from Merck in 2021 and reports its financial figures in US dollars, with its primary listing on the New York Stock Exchange under the ticker OGN. The company usually reports quarterly earnings and hosts conference calls that outline its performance in women’s health, biosimilars and established brands, and the next call is expected around early August based on recent years’ timing. Reuters coverage of recent Organon results

The most recent quarterly report, published in early May 2026, showed that Organon generated several billion dollars in annualized revenue across its three reporting segments, with management confirming full year guidance ranges for 2026. In that set of results, the company highlighted stable demand for key contraceptive products and ongoing work to manage pricing pressures in mature portfolios, giving investors a baseline ahead of the next earnings release. Organon quarterly financial results

Analyst views and sector comparison

Analyst consensus on Organon & Co continues to reflect a mixed but stable stance, with several Wall Street houses rating the stock between Hold and Buy and publishing price targets that factor in the company’s debt profile and cash generation. According to data aggregated by MarketScreener and other analyst platforms, Organon shares have an average target in the mid tens of dollars, which implies moderate upside from recent trading levels. MarketScreener analyst consensus on Organon

In the broader health care sector, Organon is often compared with companies such as Viatris and other spin offs from larger pharmaceutical groups, as well as specialist women’s health firms. Recent sector reports from brokers including Goldman Sachs and Morgan Stanley have underlined that demand in women’s health and fertility products remains robust, but competition and pricing dynamics require careful management of research and development spending. Organon’s positioning as a focused women’s health and biosimilars player is a central theme in these comparisons, keeping the stock relevant for investors looking at defensive health care exposure.

How Organon generates its revenue

Organon & Co generates its revenue primarily through prescription medicines in women’s health, biosimilars and a portfolio of established brands. The women’s health segment includes contraceptive products such as Nexplanon, a long acting reversible contraceptive implant that is widely used in many countries and provides steady recurring revenue. The biosimilars segment covers follow on versions of biologic medicines, often in partnership with other pharmaceutical companies, while the established brands segment monetizes mature products in cardiovascular and other therapeutic areas. These three segments together provide a diversified cash flow base that supports debt service and dividend payments.

Where Organon stock trades today

Organon & Co shares most recently traded around 20.50 US dollars on the NYSE, based on June 26, 2026 closing data, with the stock moving broadly in line with other mid cap health care names over recent weeks.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.